What is the diagnostic approach for Guillain‑Barré syndrome?

Diagnosis of Guillain-Barré Syndrome

GBS diagnosis is primarily clinical, requiring progressive bilateral weakness with decreased/absent reflexes, supported by CSF showing albumino-cytological dissociation (elevated protein with normal cell count) and electrodiagnostic evidence of polyradiculoneuropathy. 1

Required Diagnostic Features

The diagnosis hinges on two mandatory clinical criteria 1:

• Progressive bilateral weakness of arms and/or legs (may initially involve only legs)
• Absent or decreased tendon reflexes in affected limbs at some point during the clinical course

Clinical Presentation Pattern

Suspect GBS when you see rapidly progressive bilateral leg weakness ascending to arms over days to 2 weeks, typically following a respiratory or gastrointestinal infection 1-6 weeks prior 1. The classic presentation includes:

• Distal paresthesias or sensory loss
• Weakness starting in legs, progressing to arms and cranial muscles
• Hyporeflexia/areflexia (present in almost all patients at nadir)
• Dysautonomia (blood pressure/heart rate instability, pupillary dysfunction)
• Pain (muscular, radicular, or neuropathic)
• Maximum disability reached within 2 weeks in most cases

Critical timing red flags: If maximum disability occurs within 24 hours or progression continues beyond 4 weeks, strongly consider alternative diagnoses 1.

Ancillary Investigations

Cerebrospinal Fluid Analysis

Perform lumbar puncture early to rule out mimics 1. The classic finding is albumino-cytological dissociation:

• Elevated CSF protein with normal cell count
• However, protein is normal in 30-50% of patients in week 1 and 10-30% in week 2 - normal protein does NOT exclude GBS 1
• CSF pleocytosis >50 cells/μl essentially rules out GBS - suggests leptomeningeal malignancy or infectious polyradiculitis instead 1
• Mild pleocytosis (10-50 cells/μl) is compatible with GBS but warrants investigation for infectious causes

Electrodiagnostic Studies

Nerve conduction studies are not required for diagnosis but should be performed when possible, especially in atypical presentations 1. Typical findings include:

• Sensorimotor polyradiculoneuropathy/polyneuropathy
• Reduced conduction velocities, reduced amplitudes, temporal dispersion, conduction blocks
• "Sural sparing pattern" - normal sural sensory nerve action potential while median/ulnar sensory potentials are abnormal/absent

Important caveat: Electrophysiology may be completely normal in the first week or with proximal/mild disease - repeat testing at 2-3 weeks if initial studies are normal but clinical suspicion remains high 1.

Laboratory Testing

Obtain complete blood count, glucose, electrolytes, kidney and liver function to exclude metabolic causes of acute flaccid paralysis 1.

Anti-ganglioside antibody testing has limited value - positive results can support diagnosis when uncertain, but negative results do not exclude GBS 1. Exception: Anti-GQ1b antibodies are found in 90% of Miller Fisher syndrome cases and should be tested when MFS is suspected (ophthalmoplegia, areflexia, ataxia) 1.

Do not delay treatment waiting for antibody results 1.

Features That Cast Doubt on GBS Diagnosis

Be cautious and reconsider the diagnosis if you encounter 1:

• CSF pleocytosis >50 cells/μl
• Marked persistent asymmetry of weakness
• Bladder/bowel dysfunction at onset or persistent throughout
• Severe respiratory dysfunction with minimal limb weakness at onset
• Fever at onset
• Sharp sensory level suggesting spinal cord pathology
• Hyperreflexia, clonus, or extensor plantar responses
• Altered consciousness (except in Bickerstaff brainstem encephalitis)
• Progression >4 weeks from symptom onset

Clinical Variants to Recognize

Beyond classic sensorimotor GBS, recognize these variants 1:

• Pure motor variant - weakness without sensory signs (may have normal/exaggerated reflexes in AMAN subtype)
• Miller Fisher syndrome - ophthalmoplegia, areflexia, ataxia
• Pharyngeal-cervical-brachial weakness - cranial nerve and upper limb predominance
• Paraparetic variant - lower limb predominance
• Bilateral facial palsy with paresthesias

Pediatric pitfall: Children <6 years may present atypically with poorly localized pain, refusal to bear weight, irritability, meningism, or unsteady gait rather than classic weakness 1.

Diagnostic Algorithm

1. Identify progressive bilateral weakness with areflexia developing over days to 4 weeks
2. Perform CSF analysis - expect elevated protein with normal cells (but normal protein doesn't exclude diagnosis)
3. Obtain nerve conduction studies - expect polyradiculoneuropathy pattern (but normal early studies don't exclude diagnosis)
4. Exclude mimics with basic labs and consider imaging if atypical features present
5. Start treatment immediately if diagnosis is likely - don't wait for confirmatory tests 1

The 2023 EAN/PNS guidelines 2 provide the most current evidence-based diagnostic framework, emphasizing that GBS remains a clinical diagnosis supported by, but not dependent on, ancillary testing.